4.7 Article

Association of fish oil supplement use with preservation of brain volume and cognitive function

Journal

ALZHEIMERS & DEMENTIA
Volume 11, Issue 2, Pages 226-235

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2014.02.005

Keywords

Alzheimer's disease; Brain atrophy; Cognition; Docosahexaenoic acid; Omega-3

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  3. Abbott
  4. Alzheimer's Drug Discovery Foundation
  5. Amorfix Life Sciences Ltd
  6. AstraZeneca
  7. Bayer HealthCare
  8. BioClinica, Inc
  9. Biogen Idec, Inc
  10. Bristol-Myers Squibb Company
  11. Eisai Inc
  12. Elan Pharmaceuticals, Inc
  13. Eli Lilly and Company
  14. F. Hoffmann-La Roche Ltd, company Genentech, Inc
  15. GE Healthcare
  16. Innogenetics, N.V.
  17. IXICO Ltd
  18. Janssen Alzheimer Immunotherapy Research AMP
  19. Development, LLC
  20. Johnson AMP
  21. Johnson Pharmaceutical Research AMP
  22. Development LLC
  23. Medpace, Inc
  24. Merck Co, Inc
  25. Meso Scale Diagnostics, LLC
  26. Novartis Pharmaceuticals Corporation
  27. Pfizer Inc
  28. Servier
  29. Synarc Inc
  30. Takeda Pharmaceutical Company
  31. Canadian Institutes of Health Research
  32. NIH [P30 AG010129, K01 AG030514]
  33. Alzheimer's Association

Ask authors/readers for more resources

Objective: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. Methods: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. Results: FOS use during follow-up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini-Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE epsilon 4 negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available